AbbVie to acquire Apogee for about $135 a share, expects to close Q3 2026
MLex summary: Chicago-based AbbVie agreed to acquire San Francisco and Boston-based Apogee Therapeutics for $135.11 per share, giving it a total equity valuation of about $10.9 billion. Apogee’s lead asset, zumilokibart...To view the full article, register now.
Already a subscriber? Click here to view full article